Monovalent Rotavirus Vaccine Efficacy Against Different Rotavirus Genotypes: A Pooled Analysis of Phase II and III Trial Data
Authors:
Open Access
- 29 August 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (3) , e1150-e1156
Abstract
Background: Rotavirus vaccine performance appears worse in countries with high rotavirus genotype diversity. Evidence suggests diminished vaccine efficacy (VE) against G2P[4], which is heterotypic with existing monovalent rotavirus vaccine formulations. Most studies assessing genotype-specific VE have been underpowered and inconclusive. Methods: We pooled individual-level data from 10 Phase II and III clinical trials of rotavirus vaccine containing G1 and P[8] antigens (RV1) conducted between 2000 and 2012. We estimated VE against both any-severity and severe (Vesikari score ≥11) rotavirus gastroenteritis (RVGE) using binomial and multinomial logistic regression models for non-specific VE against any RVGE, genotype-specific VE, and RV1-typic VE against genotypes homotypic, partially heterotypic, or fully heterotypic with RV1 antigens. We adjusted models for concomitant oral poliovirus and RV1 vaccination and the country's designated child mortality stratum. Results: Analysis included 87 644 infants from 22 countries in the Americas, Europe, Africa, and Asia. For VE against severe RVGE, non-specific VE was 91% (95% confidence interval [CI]: 87–94%). Genotype-specific VE ranged from 96% (95% CI: 89–98%) against G1P[8] to 71% (43–85%) against G2P[4]. RV1-typic VE was 92% (95% CI: 84–96%) against partially heterotypic genotypes but 83% (67–91%) against fully heterotypic genotypes. For VE against any-severity RVGE, non-specific VE was 82% (95% CI: 75–87%). Genotype-specific VE ranged from 94% (95% CI: 86–97%) against G1P[8] to 63% (41–77%) against G2P[4]. RV1-typic VE was 83% (95% CI: 72–90%) against partially heterotypic genotypes but 63% (40–77%) against fully heterotypic genotypes. Conclusions: RV1 VE is comparatively diminished against fully heterotypic genotypes including G2P[4].Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R01 GR111026, R01 AI148127)
- NIGMS
- GlaxoSmithKline
- NIH (R01 GM124280)
This publication has 25 references indexed in Scilit:
- A Systematic Review of the Effect of Rotavirus Vaccination on Diarrhea Outcomes Among Children Younger Than 5 YearsThe Pediatric Infectious Disease Journal, 2016
- Epidemiology of group A rotavirus infection after the introduction of monovalent vaccine in the National Immunization Program of Saudi ArabiaJournal of Medical Virology, 2016
- Review of global rotavirus strain prevalence data from six years post vaccine licensure surveillance: Is there evidence of strain selection from vaccine pressure?Infection, Genetics and Evolution, 2014
- Uniformity of rotavirus strain nomenclature proposed by the Rotavirus Classification Working Group (RCWG)Archives of Virology, 2011
- Rotavirus Strain Types Circulating in Africa: Review of Studies Published during 1997–2006The Journal of Infectious Diseases, 2010
- Live Attenuated Human Rotavirus Vaccine, RIX4414, Provides Clinical Protection in Infants Against Rotavirus Strains With and Without Shared G and P GenotypesThe Pediatric Infectious Disease Journal, 2009
- Global distribution of rotavirus serotypes/genotypes and its implication for the development and implementation of an effective rotavirus vaccineReviews in Medical Virology, 2004
- Global Illness and Deaths Caused by Rotavirus Disease in ChildrenEmerging Infectious Diseases, 2003
- Sieve analysisJournal of Clinical Epidemiology, 2001
- Rotavirus Disease in Finnish Children: Use of Numerical Scores for Clinical Severity of Diarrhoeal EpisodesScandinavian Journal of Infectious Diseases, 1990